Androisoxazole

Androisoxazole
Clinical data
Trade namesAndroxan, Neo-Ponden, Neo-Pondus
Other names17α-Methyl-5α-androstano[3,2-c]isoxazol-17β-ol
Routes of
administration		By mouth
Drug classAndrogen; Anabolic steroid
Identifiers
  • 2,3,3a,3b,4,5,5a,6,10,10a,10b,11,12,12a-tetradecahydro-1,10a,12a-trimethyl-1H-cyclopenta[7,8]phenanthro[2,3-c]isoxazol-1-ol
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H31NO2
Molar mass329.484 g·mol−1
3D model (JSmol)
  • O[C@@]5(C)CC[C@H]4[C@H]3[C@@H]([C@]2(Cc1c(noc1)C[C@@H]2CC3)C)CC[C@@]45C
  • InChI=1S/C21H31NO2/c1-19-11-13-12-24-22-18(13)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)23/h12,14-17,23H,4-11H2,1-3H3/t14-,15+,16-,17-,19-,20-,21-/m0/s1 checkY
  • Key:NSYTUNFHWYMMHU-IYRCEVNGSA-N checkY
  (verify)

Androisoxazole (brand names Androxan, Neo-Ponden, Neo-Pondus), also known as 17α-methyl-5α-androstano[3,2-c]isoxazol-17β-ol, is an orally active anabolic-androgenic steroid (AAS) and a 17α-alkylated derivative of dihydrotestosterone (DHT) that is marketed in Spain and Italy.[1][2][3][4] It is closely related to stanozolol, differing only in having an isoxazole instead of pyrazole ring fused to the A ring,[4] and is also related to furazabol, prostanozol, and danazol.

  1. ^ Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 63–. ISBN 978-3-88763-075-1.
  2. ^ Charles D. Kochakian (6 December 2012). Anabolic-Androgenic Steroids. Springer Science & Business Media. pp. 384–. ISBN 978-3-642-66353-6.
  3. ^ ANTONINI FM, VERDI G (October 1961). "[Preliminary results of experience with a new anabolic steroid, "androisoxazole," in the aged.]". Minerva Medica (in Italian). 52: 3437–41. PMID 13861810.
  4. ^ a b ARNOLD A, POTTS GO, BEYLER AL (December 1963). "Relative Oral Anabolic to Androgenic Activity Ratios of Androisoxazole, Ethylestrenol, Methylandrostenolisoxazole and Testosterone". Acta Endocrinologica. 44 (4): 490–8. doi:10.1530/acta.0.0440490. PMID 14082537.